Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

被引：0
|
作者：
Jasmeet Chadha Singh
Yelena Novik
Stacey Stein
Matthew Volm
Marlene Meyers
Julia Smith
Coral Omene
James Speyer
Robert Schneider
Komal Jhaveri
Silvia Formenti
Victoria Kyriakou
Benson Joseph
Judith D Goldberg
Xiaochun Li
Sylvia Adams
Amy Tiersten
机构：
[1] New York University Medical Center,Department of Medicine, Division of Hematology
[2] New York University Cancer institute,Oncology
[3] Yale Medical Center,Department of Medicine, Division of Hematology
[4] New York University Medical Center,Oncology
[5] NYU Cancer Institute,Department of Radiation Oncology
[6] New York University School of Medicine,Clinical trials office
[7] Mt Sinai School of Medicine,Division of Biostatistics
[8] Mt Sinai School of Medicine,Department of Medicine, Division of Hematology
来源：
Breast Cancer Research | / 16卷
关键词：
Trastuzumab; Carboplatin; Cetuximab; International Normalize Ratio; Everolimus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial
    O'Shaughnessy, Joyce
    Wright, Gail S.
    Thummala, Anu R.
    Danso, Michael A.
    Popovic, Lazar
    Pluard, Timothy J.
    Han, Hyo S.
    Vojnovic, Zeljko
    Vasev, Nikola
    Ma, Ling
    Richards, Donald A.
    Wilks, Sharon T.
    Milenkovic, Dusan
    Xiao, Jie
    Sorrentino, Jessica A.
    Horton, Janet
    Tan, Antoinette R.
    CANCER RESEARCH, 2021, 81 (04)
  • [42] Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant HER2-negative metastatic breast cancer
    Zelnak, Amelia Bruce
    Paplomata, Elisavet
    Murali, Sujatha
    Vallabhaneni, Geetha D.
    Kaklamani, Virginia G.
    Li, Xiaoxian
    Liu, Yuan
    O'Regan, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2
    Goel, Shom
    Tan, Antoinette R.
    Rugo, Hope S.
    Aftimos, Philippe
    Andric, Zoran
    Beelen, Andrew
    Zhang, Jingshan
    Yi, John S.
    Malik, Rajesh
    O'Shaughnessy, Joyce
    FUTURE ONCOLOGY, 2022, 18 (33) : 3701 - 3711
  • [44] COMBINATION OF CARBOPLATIN (C) AND GEMCITABINE (G) IN METASTATIC TRIPLE NEGATIVE (TN) BREAST CANCER. A PILOT STUDY
    Maisano, Roberto
    Azzarello, Domenico
    Del Medico, Pietro
    Giannicola, Rocco
    Giuffre, Caterina
    Panuccio, Vincenzo
    Raffaele, Mario
    Zavettieri, Maria
    Nardi, Mario
    ANNALS OF ONCOLOGY, 2009, 20
  • [45] A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
    Ma, Cynthia X.
    Ellis, Matthew J. C.
    Petroni, Gina R.
    Guo, Zhanfang
    Cai, Shi-rong
    Ryan, Christine E.
    Lockhart, A. Craig
    Naughton, Michael J.
    Pluard, Timothy J.
    Brenin, Christiana M.
    Picus, Joel
    Creekmore, Allison N.
    Mwandoro, Tibu
    Yarde, Erin R.
    Reed, Jerry
    Ebbert, Mark
    Bernard, Philip S.
    Watson, Mark
    Doyle, Laurence A.
    Dancey, Janet
    Piwnica-Worms, Helen
    Fracasso, Paula M.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 483 - 492
  • [46] Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer
    Yuan, Y.
    Frankel, P.
    Li, M.
    Kruper, L.
    Jones, V.
    Treece, T.
    Waisman, J.
    Yim, J.
    Tumyan, L.
    Schmolze, D.
    Hurria, A.
    Yeon, C.
    Mortimer, J.
    Somlo, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [47] A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
    Cynthia X. Ma
    Matthew J. C. Ellis
    Gina R. Petroni
    Zhanfang Guo
    Shi-rong Cai
    Christine E. Ryan
    A. Craig Lockhart
    Michael J. Naughton
    Timothy J. Pluard
    Christiana M. Brenin
    Joel Picus
    Allison N. Creekmore
    Tibu Mwandoro
    Erin R. Yarde
    Jerry Reed
    Mark Ebbert
    Philip S. Bernard
    Mark Watson
    Laurence A. Doyle
    Janet Dancey
    Helen Piwnica-Worms
    Paula M. Fracasso
    Breast Cancer Research and Treatment, 2013, 137 : 483 - 492
  • [48] A Phase I Study Accessing Immunotherapy Combination of Balstilimab and Ivermectin in Patients with Metastatic Triple Negative Breast Cancer
    Yuan, Yuan
    Shiao, Stephen
    Tighiouart, Mourad
    Mita, Monica
    Bitar, Jin-Sun
    McAndrew, Philomena
    Dorothy, Park
    El-Masry, Maryliza
    Frankel, Paul
    Lee, Peter
    CANCER RESEARCH, 2024, 84 (09)
  • [49] A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC)
    Bagegni, Nusayba Ali
    Nehring, Leslie
    Anderson, Jill
    Haas, Brittney
    Luo, Jingqin
    Trivedi, Meghna S.
    Kennedy, Laura Carpin
    Bhave, Manali A.
    Daily, Karen Colleen
    Razaq, Wajeeha
    Lu, Yiling
    Wang, Wei-Lien
    Wulf, Gerburg M.
    Said, Rabih
    Ma, Cynthia X.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial
    O'Shaughnessy, J.
    Wright, G. S.
    Thummala, A.
    Danso, M.
    Popovic, L. S.
    Pluard, T.
    Han, H. S.
    Vojnovic, Z.
    Vasev, N.
    Ma, L.
    Richards, D. A.
    Wilks, S.
    Milenkovic, D. M.
    Sorrentino, J. A.
    Yang, Z.
    Horton, J. K.
    Tan, A. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 860 - +
12345